Therapeutic agent for meibomian dysfunction
US11951098B2 · kind B2 · utility
0Cited by
18References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 16, 2023 |
| Grant date | Apr 9, 2024 |
| Priority date | — |
| Expiry date | Feb 16, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.